Table 4.

Years of E+P use, genetic variation, and risk of breast cancer

PolymorphismYears of E+P use
Never
1-<10
≥10
Cases/controlsOR (95% CI)*Cases/controlsOR (95% CI)*Cases/controlsOR (95% CI)*
COMT Val108/158Met
    Met/Met37/841.0 (Reference)25/381.4 (0.7-2.8)15/172.0 (0.9-4.4)
    Met/Val or Val/Val95/2630.8 (0.5-1.3)45/811.2 (0.7-2.0)52/751.5 (0.9-2.5)
Pinteraction0.88
CYP1A1 Ile462Val
    Ile/Ile141/3411.0 (Reference)66/1141.3 (0.9-2.0)68/951.7 (1.2-2.5)
    Ile/Val or Val/Val8/310.6 (0.3-1.5)8/102.1 (0.8-5.4)9/54.7 (1.5-14.4)
Pinteraction0.04
CYP1A1 MspI
    T/T127/2801.0 (Reference)62/981.4 (0.9-2.0)55/851.4 (0.9-2.1)
    T/C or C/C23/940.6 (0.3-0.9)12/251.1 (0.5-2.3)22/153.2 (1.6-6.5)
Pinteraction0.003
CYP17A1 5′ UTR
    A/A43/1311.0 (Reference)26/511.5 (0.8-2.8)30/392.3 (1.2-4.1)
    A/G or G/G107/2501.3 (0.9-2.0)50/752.0 (1.2-3.3)47/622.3 (1.4-3.9)
Pinteraction0.54
CYP19A1 Arg264Cys
    Arg/Arg136/3531.0 (Reference)74/1161.6 (1.1-2.3)67/911.9 (1.3-2.7)
    Arg/Cys or Cys/Cys14/251.3 (0.7-2.7)2/70.8 (0.2-4.1)9/102.3 (0.9-5.8)
Pinteraction0.77
CYP19A1 3′ UTR
    C/C33/981.0 (Reference)15/311.3 (0.6-2.8)19/282.0 (1.0-4.2)
    C/T + T/T117/2781.3 (0.8-2.0)60/941.9 (1.1-3.2)58/732.3 (1.4-4.0)
Pinteraction0.88
CYP1B1 Arg48Gly
    Arg/Arg82/1971.0 (Reference)38/631.4 (0.9-2.3)38/541.6 (1.0-2.7)
    Arg/Gly or Gly/Gly68/1791.0 (0.7-1.4)36/601.4 (0.8-2.3)36/452.0 (1.2-3.4)
Pinteraction0.51
CYP1B1 Val432Leu
    Leu/Leu40/1381.0 (Reference)26/412.3 (1.2-4.2)32/303.7 (2.0-6.9)
    Leu/Val or Val/Val109/2391.7 (1.1-2.6)50/852.0 (1.2-3.4)45/712.2 (1.3-3.8)
Pinteraction0.007
CYP1B1 Asn453Ser
    Asn/Asn105/2401.0 (Reference)43/891.1 (0.7-1.7)47/701.5 (1.0-2.4)
    Asn/Ser or Ser/Ser45/1370.8 (0.5-1.1)32/362.0 (1.1-3.5)30/312.2 (1.2-3.8)
Pinteraction0.04
ESR1 Ser10Ser
    T/T39/951.0 (Reference)18/480.9 (0.4-1.7)22/291.8 (0.9-3.7)
    C/T + T/T111/2841.0 (0.6-1.5)57/761.8 (1.1-3.1)55/721.8 (1.1-3.1)
Pinteraction0.61
GSTP1 Ile105Val
    Ile/Ile66/1561.0 (Reference)31/551.3 (0.7-2.2)32/431.8 (1.0-3.1)
    Ile/Val or Val/Val84/2230.9 (0.6-1.3)45/711.5 (0.9-2.4)45/581.8 (1.1-2.9)
Pinteraction0.66
PGR +331G/A
    G/G139/3441.0 (Reference)73/1141.5 (1.0-2.2)67/861.9 (1.3 -2.8)
    G/A or A/A11/370.7 (0.3-1.4)4/130.7 (0.2-2.2)11/151.7 (0.7-3.8)
Pinteraction0.74
PGR Val660Leu
    Val/Val114/2721.0 (Reference)45/881.2 (0.8-1.9)45/751.4 (0.9-2.1)
    Leu/Val or Leu/Leu36/1050.9 (0.6-1.3)31/381.9 (1.1-3.2)32/263.1 (1.8-5.6)
Pinteraction0.01
SHBG 5′ UTR
    G/G87/2201.0 (Reference)42/741.4 (0.9-2.2)35/521.6 (1.0-2.7)
    G/A or A/A61/1570.9 (0.6-1.4)35/531.6 (0.9-2.6)42/482.2 (1.3-3.6)
Pinteraction0.30
SHBG Asp356Asn
    Asp/Asp119/3091.0 (Reference)58/961.5 (1.0-2.3)66/732.3 (1.6-3.5)
    Asp/Asn or Asn/Asn31/711.2 (0.7-1.9)18/301.5 (0.8-2.9)12/281.1 (0.5-2.2)
Pinteraction0.05
SULT1A1 Arg213His
    Arg/Arg76/1681.0 (Reference)41/651.4 (0.8-2.2)32/501.4 (0.8-2.4)
    Arg/His or His/His73/2040.8 (0.6-1.2)34/621.1 (0.7-1.9)46/511.9 (1.2-3.2)
Pinteraction0.19
  • * Adjusted for age at baseline (<55, 55-<65, ≥65 y), race (White, other), body mass index (<25.0 kg/m2, 25.0-<30.0 kg/m2, ≥30.0 kg/m2, unknown), cigarette smoking (never, former, current, unknown), number of first-degree relatives with history of breast cancer (none, 1, 2+, unknown), prior breast biopsy (no, yes), and age at menopause (≤44, 45-49, ≥50 y, unknown).